Literature DB >> 6832804

Lymphokine-like products of cultured tumour cells.

Y Inoue, C L Geczy, D S Nelson, M Nelson.   

Abstract

Supernatants from cultures of rat and guinea-pig tumour cells, guinea-pig fibroblasts and kidney cells, but not rat fibroblasts, inhibited the migration of peritoneal exudate macrophages in vitro. The inhibitory activity in tumour-cell supernatants differed from that of lymphokine in being heat stable (60 degrees, 3 hr) and dialysable, not inhibited by fucose and, in the case of guinea-pig line 1 tumour, not absorbed by an anti-lymphokine immunoabsorbent. Rat lymphokine and supernatants from four cultured rat tumours and, to a lesser extent, fibroblasts induced procoagulant activity in rat peritoneal exudate macrophages. The tumour procoagulant-inducing activity was heat stable and non-dialysable. Direct procoagulant activity was also found in rat lymphokine, fibroblast and tumour culture supernatants. This activity was partly or completely heat-labile but was non-dialysable.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6832804      PMCID: PMC1454058     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  Production and in vivo effect of antibodies against guinea pig lymphokines.

Authors:  C L Geczy; W Friedrich; A L de Weck
Journal:  Cell Immunol       Date:  1975-09       Impact factor: 4.868

2.  Lymphokines. I. Use of insoluble concanavalin A for the production of migration inhibitory factor in guinea pig lymphocyte cultures.

Authors:  W Friedrich; S Lazary; C Geczy; A L de Weck
Journal:  Int Arch Allergy Appl Immunol       Date:  1975

3.  Production of macrophage migration inhbitory factor(s) (MIF) by virus-transformed cells.

Authors:  G Poste
Journal:  Exp Cell Res       Date:  1975-05       Impact factor: 3.905

4.  Production of lymphokine-like factors (cytokines) by simian virus 40-infected and simian virus 40-transformed cells.

Authors:  P E Bigazzi; T Yoshida; P A Ward; S Cohen
Journal:  Am J Pathol       Date:  1975-07       Impact factor: 4.307

5.  Concomitant immunity to syngeneic methylcholanthrene-induced tumours in mice. Occurrence and specificity of concomitant immunity.

Authors:  R Kearney; D S Nelson
Journal:  Aust J Exp Biol Med Sci       Date:  1973-12

6.  Role of monosaccharides in the interaction of two lymphocyte mediators with their target cells.

Authors:  R E Rocklin
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

7.  MIF-like activity in simian virus 40-transformed 3T3 fibroblast cultures.

Authors:  M E Hammond; R O Roblin; A M Dvorak; S S Selvaggio; P H Black; H F Dvorak
Journal:  Science       Date:  1974-09-13       Impact factor: 47.728

8.  Production and characterization of migration inhibitory factor(s) (MIF) of established lymphoid and non-lymphoid cell lines.

Authors:  P S Papageorgiou; W L Henley; P R Glade
Journal:  J Immunol       Date:  1972-02       Impact factor: 5.422

9.  Requirement for alpha-L-fucose on the macrophage membrane receptor for MIF.

Authors:  H G Remold
Journal:  J Exp Med       Date:  1973-11-01       Impact factor: 14.307

10.  Production of macrophage migration inhibition factor by continuous cell lines.

Authors:  D G Tubergen; J D Feldman; E M Pollock; R A Lerner
Journal:  J Exp Med       Date:  1972-02-01       Impact factor: 14.307

View more
  3 in total

Review 1.  The role of lymphokines in delayed-type hypersensitivity reactions.

Authors:  C L Geczy
Journal:  Springer Semin Immunopathol       Date:  1984

2.  Inhibition of normal rat macrophage functions by soluble tumor products. Effect of systemic treatment with bacterial immunomodulators.

Authors:  D Iannello; L Bonina; D Delfino; M C Berlinghieri; P Mastroeni
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Prostaglandin E2 as an immunomodulating factor released in vitro by human glioma cells.

Authors:  G M Lauro; N Di Lorenzo; M Grossi; A Maleci; B Guidetti
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.